Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | SETD2 | Q9BYW2 | 4/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640843 | 0.97 | IDO1 (0.35) | CTSSSETD2ACKR3NSD2CYP2C8 | |
| SCHEMBL13641052 | 0.95 | IDO1 (0.34) | CTSSSETD2ACKR3NSD2CYP2C8 | |
| SCHEMBL13641038 | 0.94 | CTSS (0.35) | CTSSSETD2ACKR3NSD2CYP2C8 | |
| SCHEMBL13640827 | 0.94 | IDO1 (0.35) | CTSSSETD2NSD2CYP2C8DRD2 | |
| SCHEMBL13640735 | 0.94 | SETD2 (0.37) | CTSSSETD2ACKR3NSD2CYP2C8 | |
| SCHEMBL13640819 | 0.93 | MEN1 (0.37) | CTSSSETD2NSD2CYP2C8DRD2 | |
| SCHEMBL13641010 | 0.92 | CTSS (0.36) | CTSSSETD2ACKR3NSD2CYP2C8 | |
| SCHEMBL13640862 | 0.92 | MEN1 (0.39) | CTSSSETD2NSD2CYP2C8DRD2 | |
| SCHEMBL13640898 | 0.92 | CTSS (0.36) | CTSSSETD2ACKR3NSD2CYP2C8 | |
| SCHEMBL13640779 | 0.91 | AXL (0.37) | CTSSSETD2ACKR3NSD2CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497295-B2 | Spiroindoline modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | CTSS 3839/4885SETD2 3573/4885ACKR3 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.